Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Amvuttra and Wainua Are Rivals In The Space

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

runners — Ionis and Alnylam are competing in cardiomyopathy • Source: Shutterstock

Ionis Pharmaceuticals, Inc. CEO Brett Monia said the company remains confident in the Phase III trial design for Wainua (eplontersen) for the treatment of hereditary transthyretin mediated amyloidosis (ATTR) cardiomyopathy, days after rival Alnylam Pharmaceuticals Inc. made changes to the endpoint and timeline of an ongoing Phase III trial testing Amvuttra (vutrisiran) for the same indication.

Key Takeaways

Ionis responded to investor questions about the Phase III development program for Wainua in ATTR cardiomyopathy, after Alnylam announced changes to the study of a rival drug.

Alnylam’s announcement on 15 February during the company’s fourth quarter sales and earnings call startled some investors, as the Phase...